| 2022 |
Haider IT, Sawatsky A, Zhu Y, Page R, Kostenuik PJ, Boyd SK, Edwards WB. Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys. Bone. November 2022;164:116517. |
0 |
0 |
| 1999 |
Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. November 1999;14(11):1805-1815. |
25 |
22 |
| 2008 |
Li X, Ominsky MS, Niu Q, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. June 2008;23(6):860-869. |
63 |
59 |
| 2009 |
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu Q-T, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. April 2009;24(4):578-588. |
57 |
52 |
| 2015 |
Ominsky MS, Libanati C, Niu Q-T, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous bmd gains with denosumab. J Bone Miner Res. July 2015;30(7):1280-1289. |
12 |
7 |
| 2023 |
Haider IT, Loundagin LL, Sawatsky A, Kostenuik PJ, Boyd SK, Edwards WB. Twelve months of denosumab and/or alendronate is associated with improved bone fatigue life, microarchitecture, and density in ovariectomized cynomolgus monkeys. J Bone Miner Res. March 2023;38(3):403-413. |
1 |
0 |